Bisphosphonates and osteonecrosis of the jaws

Journal of Dental Education

Volumn 72, Issue 8, 2008, Pages 919-929

  Mariotti, Angelo ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Etiology; Management; Osteonecrosis of the jaw; Prevalence; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; HUMAN; JAW DISEASE; REVIEW; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; RISK FACTORS;

EID: 53449095025     PISSN: 00220337     EISSN: 19307837     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Fiacchi-Hudak D. The importance of medical-dental collaboration in bisphosphonate therapy. Grand Rounds 2007;2(3):34-5.
2. Wade ML, Suzuki JB. Issues related to diagnosis and treatment of bisphosphonate-induced osteonecrosis of the jaws. Grand Rounds 2007;2(3):46-53.
3. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137(8):1144-50.
4. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Approved by the Board of Trustees, September 25, 2006. J Oral Maxillofac Surg 2007;65(3):369-76.
5. Wilensky AO. Osteomyelitis of the jaw. Arch Surg 1932;25(1):183-237.
6. Hankey GT. Osteomyelitis (necrosis) of the jaws: its pathology and treatment. Br Dent J 1938;65(9):549-61.
7. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212(5065):901-3.
8. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75(6):451-61.
9. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporosis Rep 2003;1(2):45-52.
10. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17(2):137-44.
11. Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003;12(Suppl 2):S37-S44.
12. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538-44.
13. Cecchini MG, Fellix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987;2(2):135-42.
14. Chapurlat RD, Delmas PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006;2(4):211-9.
15. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37.
16. Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7(5):513-22.
17. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39(4):668-77.
18. Mühlemann HR, Bowles D, Schatt A, Bernimoulin JP. Effect of diphosphonate on human supragingival calculus. Helvetica Odontol Acta 1970;14(1):31-3.
19. Rocha ML, Malacara JM, Sanchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effects of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol 2004;75(12):1579-85.
20. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76(7):1113-22.
21. Kelleher FC, McKenna M, Collins C, Brady G, Collins I, Crown J. Bisphosphonate-induced osteonecrosis of the jaws: unravelling uncertainty in disease causality. Acta Oncol 2007;46(5):702-4.
22. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753-61.
23. McMahon RE, Bouquot JE, Clueck CJ, Spolnik KJ, Adams WR. Osteonecrosis: a multifactorial etiology. J Oral Maxillofac Surg 2004;62(7):904-5.
24. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 2007;89(8):1727-34.
25. Nguyen T, Zacharin MR. Pamidronate treatment of steroid-associated osteonecrosis in young patients treated for acute lymphoblastic leukemia: two-year outcomes. J Pediatr Endocrinol Metab 2006;19(2):161-7.
26. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
27. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-K. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 2005;136(12):1658-68.
28. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91.
29. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353(1):99-102.
30. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353(1):99-102.
31. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7.
32. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24(6):945-52.
33. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-23.
34. Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol 2007;78(9):1664-9.
35. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24(Suppl 18S):8528.
36. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
37. Marx RE. Risks, prevention, and management of oral bisphosphonate-induced osteonecrosis. In: Marx RE, ed. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. Chicago: Quintessence Books, 2007:77-95.
38. Zarychanski R, Elpee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81(1):73-5.
39. Carter G, Gross AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182(8):413-5.